Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies

Michael Lee, Frederique Bard, Kelly Johnson-Wood, Celeste Lee, Kang Hu, Sue G. Griffith, Ronald S. Black, Dale Schenk, Peter Seubert

Research output: Contribution to journalArticlepeer-review

113 Scopus citations

Abstract

Serum samples from Alzheimer's disease (AD) patients immunized with Aβ42 (AN1792) were analyzed to determine the induced antibody properties including precise amyloid-β peptide (Aβ) epitopes and amyloid plaque-binding characteristics. The predominant response in these patients is independent of whether or not meningoencephalitis developed and is against the free amino terminus of Aβ. The immunostaining of amyloid plaques in brain tissue by patient sera is adsorbable by a linear Aβ 1-8 peptide, demonstrating that the antibodies are directed predominantly to this epitope and not dependent on Aβ conformations or aggregates specific to plaques. Furthermore, the antibodies are not capable of binding amyloid precursor protein and would be predicted to be competent in facilitating clearance of amyloid plaques in AD brains.

Original languageEnglish (US)
Pages (from-to)430-435
Number of pages6
JournalAnnals of Neurology
Volume58
Issue number3
DOIs
StatePublished - Sep 1 2005

Fingerprint Dive into the research topics of 'Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies'. Together they form a unique fingerprint.

Cite this